Abstract / Summary
Mengshen Wang,1 Xiaohua Liu,2 Wei Ding,1 Kai Xu,3 Jingyan Feng,4 Di Lyu,11Department of Thyroid and Breast Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 2Department of Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People’s Republic of China; 3Department of Thyroid and Breast Surgery, Xuzhou First People’s Hospital, Xuzhou, Jiangsu, 221000, People’s Republic of China; 4Department of Mammary Gland, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, 221005, People’s Republic of ChinaCorrespondence: Di Lyu, Department of Thyroid and Breast Surgery, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou, Jiangsu, 221004, People’s Republic of China, Tel +86 18205211781, Email 18205211781@163.comObjective: This study aimed to develop an interpretable model integrating dynamic MRI intratumoral heterogeneity (ITH) scores for early assessment of pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC).Methods: A total of 400 breast cancer patients from three centers were prospectively enrolled. Among them, 300 patients from the Affiliated Hospital of Xuzhou Medical University were randomly assigned in a 7:3 ratio to a training set (n = 210) and an internal validation set (n = 90), while 50 patients from Xuzhou Cancer Hospital and 50 patients from Xuzhou First People’s Hospital constituted the external validation set. Clinicopathological characteristics and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data were collected. The baseline MRI-ITH score (ITH0) and dynamic changes at 2 weeks (MRI-Delta-ITH1) and 4 weeks (MRI-Delta-ITH2) after treatment initiation were calculated. Seven predictive models were constructed using logistic regression, and SHAP analysis was used to interpret feature contributions.Results: The model integrating clinical features and MRI-ΔITH2 yielded the best performance, with area under the receiver operating characteristic curve (AUC) values of 0.940, 0.873, and 0.917 in the training, internal validation, and external validation sets, respectively. SHAP analysis revealed that MRI-ΔITH2 (31.7%), PR status (24.3%), and HER-2 status (18.8%) were the core predictive factors.Conclusion: A predictive model integrating dynamic MRI-ITH scores with clinicopathological features demonstrated favorable performance for early assessment of pCR after NAC in breast cancer patients. Further multicenter validation is warranted before clinical translation.Keywords: breast cancer, neoadjuvant chemotherapy, magnetic resonance imaging, intratumoral heterogeneity, SHapley Additive exPlanations, prediction model
Topics
Primary Source
Journal of Multidisciplinary Healthcare
Ask Prognia AI
Have questions about this review article?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.